艾曲泊帕治疗中国儿童ITP的长期真实世界观察研究
该前瞻性纵向队列研究纳入116例持续或慢性ITP患儿,艾曲泊帕治疗至少3个月,总体缓解率76.7%,完全缓解率45.7%,中位血小板计数第1周即升高并维持,出血症状比例从基线83.61%降至6个月9.88%,不良事件均为1-2级。
要点
- 艾曲泊帕治疗儿童持续或慢性ITP总体缓解率76.7%,完全缓解率45.7%。
- 中位血小板计数第1周即升高并维持整个治疗期。
- 出血症状比例从基线83.61%降至6个月9.88%。
核心结论
- 长期艾曲泊帕治疗对多数儿童持续或慢性ITP安全、耐受良好,能维持血小板计数并减少出血。
研究设计与样本
- 前瞻性、观察性、纵向队列研究,纳入116例持续或慢性ITP患儿,艾曲泊帕治疗至少3个月。
主要发现
- 89例(76.7%)达总体缓解,53例(45.7%)达完全缓解,36例(31.0%)达缓解。
- 中位血小板计数第1周即升高并维持整个治疗期。
- 治疗期间1-4级出血症状比例从基线83.61%降至6个月9.88%(仅报告1级)。
- 所有不良事件均为1或2级,未报告严重不良事件、白内障、恶性肿瘤或血栓形成。
关键数值与推荐
- 中位有效剂量:≤5岁为25 mg/日,6-11岁为50 mg/日,≥12岁为50 mg/日。
临床怎么用
- 艾曲泊帕可用于儿童持续或慢性ITP的长期治疗,以维持血小板计数并减少出血。
局限性
- 需结合未来研究以确定艾曲泊帕在东亚裔儿童ITP管理中的最佳使用方式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with isolated thrombocytopenia and risk of hemorrhage. Treatment with eltrombopag increases and maintains hemostatic platelet counts; however, to date, long-term data are lacking on the outcome of children with ITP who are treated with eltrombopag. This prospective, observational, longitudinal cohort study evaluated the efficacy and safety of eltrombopag in pediatric patients with persistent or chronic ITP. For the 116 pediatric patients enrolled, duration of eltrombopag treatment was at least 3 months. Median effective dose was 25 mg/day, 50 mg/day, and 50 mg/day, respectively, for children age 5 years or younger, 6 to 11 years, or 12 years or older. In all, 89 patients (76.7%) achieved overall response, 53 (45.7%) achieved complete response, and 36 (31.0%) achieved response. Median platelet counts increased by week 1 and were sustained throughout the treatment period. During treatment with eltrombopag, the proportion of patients with grade 1 to 4 bleeding symptoms decreased from 83.61% at baseline to 9.88% at 6 months when only grade 1 was reported. Forty-three patients (37.1%) reported using concomitant medications at study entry, which was reduced to 1 patient (2.5%) who needed concomitant medications at 12 months. All adverse events were grade 1 or 2 according to Common Terminology Criteria for Adverse Events. No serious adverse events, cataracts, malignancies, or thromboses were reported during the study. Long-term treatment with eltrombopag was generally safe, well tolerated, and effective in maintaining platelet counts and reducing bleeding in most pediatric patients with persistent or chronic ITP. Combined with future studies, these findings will help establish how eltrombopag should best be used in the management of pediatric patients with East Asian ancestry.
引用
- Cheng X, Fu L, Ma J, et al. Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice. Blood Adv. 2021. PMID: 34605871. doi:10.1182/bloodadvances.2020004110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。